Dr. Andrew Cheng has served as Akero’s president and chief executive officer since September 2018. Before joining the company, he served for 19 years at Gilead Sciences, where his last role was chief medical officer. During his tenure, he was responsible for the clinical development of the HIV program resulting in 11 FDA/EMA approved products. Dr. Cheng serves on the board of directors of Vera Therapeutics. He previously served on the board of directors of MorphoSys (acquired by Novartis), Arbutus Biopharma, and privately held Syntimmune (acquired by Alexion). Dr. Cheng has a BA in biology from Johns Hopkins University and an M.D. and Ph.D. in cellular and molecular biology from Columbia University College of Physicians and Surgeons. He completed his internal medicine residency at UCLA and was board certified in internal medicine.
Manage Consent
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.
The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.